Quantcast

Latest Genous Stories

2014-06-12 08:28:30

ZWOLLE, The Netherlands, June 12, 2014 /PRNewswire/ -- Randomized Evaluation of short-term DUal antiplatelet therapy in patients with acute coronary syndrome treated with the COMBOTM Dual-Therapy StEnt The Principal Investigators of the REDUCE trial announce the enrolment of the first patient in the REDUCE trial with the OrbusNeich COMBO Dual Therapy Stent at Isala Hospital, Zwolle, the Netherlands. According to the local PI and treating physician, Doctor E....

2014-05-23 04:20:45

COMBO(TM) Dual Therapy Stent shown to actively promote rapid endothelialization and deliver long-term, true vessel healing HONG KONG, May 23, 2014 /PRNewswire/ -- OrbusNeich today announced long-term results from its REMEDEE Trial. In addition to showing that the COMBO(TM) Dual Therapy Stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing. Key findings include: -...

2014-04-24 08:32:29

HONG KONG, April 24, 2014 /PRNewswire/ -- OrbusNeich today announced the appointment of B. Wayne Johnson as president and chief operating officer and the expansion of its board of directors with the additions of Scott Addonizio, vice president & general manager, Shenzhen operations; David Camp, vice president, sales & marketing, Europe, the Middle East and Africa (EMEA); and Christophe Lee, vice president and chief financial officer. Mr. Johnson has more than 32...

2014-03-28 08:27:19

Post-Market Registry to Evaluate Long-Term Safety and Performance in Routine Practice HONG KONG, March 28, 2014 /PRNewswire/ -- OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary...

2014-03-05 12:27:46

-- Rapid polymer absorption within three months coupled with drug delivery profile up to nine months provides for excellent healing -- DURHAM, N.C., March 5, 2014 /PRNewswire/ --- Micell Technologies, Inc. today announced that the long-term clinical outcomes from the DESSOLVE I and II clinical trials recently were presented at the Cardiovascular Research Technologies (CRT) Conference held in Washington, D.C., February 22 - 25. The data presentation, "MiStent SES Clinical Program:...

2014-02-26 04:21:30

Company Initiates Joint U.S. and Japanese Registration Trial HONG KONG, Feb. 26, 2014 /PRNewswire/ -- OrbusNeich today announced that patient enrollment has been initiated in Japan in the pivotal clinical trial of the COMBO Dual Therapy Stent(TM) (COMBO Stent) employing a single Japan-U.S. protocol conducted as a Global Clinical Trial "proof-of-concept" under the framework of the joint Japan-U.S. Harmonization-By-Doing [HBD] initiative. The first patient was enrolled at Shonan...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related